Is there a role for immunotherapy in malignant pleural mesothelioma?

Alfredo Tartarone, Rosa Lerose, Michele Aieta

Research output: Contribution to journalReview article

Abstract

Malignant pleural mesothelioma (MPM) is a very aggressive malignancy, mainly caused by asbestos exposure. Patients with MPM have a poor prognosis that remained substantially unchanged in the last few years and limited effective therapeutic options with no recognized second or further-line therapy. In this context, also in view of the positive results observed in other tumor types, immunotherapy could play a relevant role. This review focuses on the most promising immunotherapies being investigated in MPM.

Original languageEnglish
Article number98
JournalMedical Oncology
Volume35
Issue number7
DOIs
Publication statusPublished - Jul 1 2018

Fingerprint

Immunotherapy
Asbestos
Neoplasms
Therapeutics
Malignant Mesothelioma

Keywords

  • CAR T cell therapy
  • Immune checkpoint inhibitors
  • Immunotherapy
  • Malignant pleural mesothelioma

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Is there a role for immunotherapy in malignant pleural mesothelioma? / Tartarone, Alfredo; Lerose, Rosa; Aieta, Michele.

In: Medical Oncology, Vol. 35, No. 7, 98, 01.07.2018.

Research output: Contribution to journalReview article

@article{ef154083300d49e785f3c4efbbe6e77f,
title = "Is there a role for immunotherapy in malignant pleural mesothelioma?",
abstract = "Malignant pleural mesothelioma (MPM) is a very aggressive malignancy, mainly caused by asbestos exposure. Patients with MPM have a poor prognosis that remained substantially unchanged in the last few years and limited effective therapeutic options with no recognized second or further-line therapy. In this context, also in view of the positive results observed in other tumor types, immunotherapy could play a relevant role. This review focuses on the most promising immunotherapies being investigated in MPM.",
keywords = "CAR T cell therapy, Immune checkpoint inhibitors, Immunotherapy, Malignant pleural mesothelioma",
author = "Alfredo Tartarone and Rosa Lerose and Michele Aieta",
year = "2018",
month = "7",
day = "1",
doi = "10.1007/s12032-018-1156-x",
language = "English",
volume = "35",
journal = "Medical Oncology",
issn = "1357-0560",
publisher = "Humana Press Inc.",
number = "7",

}

TY - JOUR

T1 - Is there a role for immunotherapy in malignant pleural mesothelioma?

AU - Tartarone, Alfredo

AU - Lerose, Rosa

AU - Aieta, Michele

PY - 2018/7/1

Y1 - 2018/7/1

N2 - Malignant pleural mesothelioma (MPM) is a very aggressive malignancy, mainly caused by asbestos exposure. Patients with MPM have a poor prognosis that remained substantially unchanged in the last few years and limited effective therapeutic options with no recognized second or further-line therapy. In this context, also in view of the positive results observed in other tumor types, immunotherapy could play a relevant role. This review focuses on the most promising immunotherapies being investigated in MPM.

AB - Malignant pleural mesothelioma (MPM) is a very aggressive malignancy, mainly caused by asbestos exposure. Patients with MPM have a poor prognosis that remained substantially unchanged in the last few years and limited effective therapeutic options with no recognized second or further-line therapy. In this context, also in view of the positive results observed in other tumor types, immunotherapy could play a relevant role. This review focuses on the most promising immunotherapies being investigated in MPM.

KW - CAR T cell therapy

KW - Immune checkpoint inhibitors

KW - Immunotherapy

KW - Malignant pleural mesothelioma

UR - http://www.scopus.com/inward/record.url?scp=85047828998&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047828998&partnerID=8YFLogxK

U2 - 10.1007/s12032-018-1156-x

DO - 10.1007/s12032-018-1156-x

M3 - Review article

VL - 35

JO - Medical Oncology

JF - Medical Oncology

SN - 1357-0560

IS - 7

M1 - 98

ER -